On January 09, 2025 Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class therapeutics using the biotech’s platform (Press release, Light Horse Therapeutics, JAN 9, 2025, View Source [SID1234649563]). Under the terms of the agreement, Light Horse will receive a $25 million upfront payment. The company is also eligible for $1 billion in further research, development and sales milestones, in addition to royalties on licensed therapeutics. Further details are undisclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Light Horse’s high-caliber team has built a cutting-edge discovery platform that rapidly enables the exploration of core biological areas of interest, the identification of novel targets and the functionalization of high-value targets," said John Tallarico, Head of Discovery Sciences at Novartis. "This collaboration has the potential to create first-in-class therapeutics capable of driving meaningful benefit for patients."

"The Novartis collaboration presents an extraordinary opportunity to leverage our unbiased genetic screening platform and proprietary chemical libraries to address novel, high-value targets previously considered hard to drug," said Light Horse CEO Markus Renschler, MD. "We are excited to work with the Novartis team to potentially accelerate the development of innovative cancer treatments over the coming years."